dpp-4 inhibitor, glp-1 receptor agonist, & sglt inhibitor therapies in the time of covid-19
Published 4 years ago • 1.7K plays • Length 47:09Download video MP4
Download video MP3
Similar videos
-
6:40
comparative effectiveness of a dpp-4 inhibitor, a sulfonylurea, a glp-1 agonist, and basal insulin
-
0:58
transforming diabetes care: discover the power of sglt2 inhibitors and glp-1 agonists
-
14:53
fundamentals of sglt2i's and glp-1ra's for cv risk
-
45:58
diabetes & exercise in the time of covid-19
-
47:29
insulin dosing & therapeutic inertia in the time of covid-19
-
57:39
continuous glucose monitoring (cgm) & beyond a1c targets in the time of covid-19
-
53:29
efl033 - glp-1 receptor agonists and sglt2 inhibitors in type 1 diabetes
-
2:43
dpp-4 inhibitors add-on to insulin reduces the risk of all-cause mortality in diabetics
-
4:38
how does sitagliptin work? dpp-4 inhibitors and glp-1 mimetics
-
2:33
dr darren mcguire debates sglt2 inhibitors and glp-1 receptor agonists as cvd prime time prevention
-
46:12
covid-19 & sick day management for people with diabetes
-
3:32
understanding how sglt2 inhibitors and glp-1 agonists work - medpage today
-
49:14
dpp4i & sglt2i: perfect partners
-
50:35
tackling therapeutic inertia: american diabetes association standard of care updates
-
2:13
peter toth, md: glp-1 agonists and sglt-2 inhibitors for diabetes
-
0:58
dr. jay shah | sglt2 inhibitors and/or glp-1ras in inpatient cardiovascular | deciphering ada 2021
-
7:43
choosing sglt2 inhibitors vs glp-1 receptor agonists
-
47:01
leveraging telehealth and remote monitoring to support patients with diabetes
-
13:54
using glp1 receptor agonists to treat cardiac patients with diabetes